First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Clinical trial NCT05627960 · RECRUITING

Trial details

NCT number: NCT05627960
Sponsor: A&G Pharmaceutical Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Triple Negative Breast Cancer Hormone-Resistant Breast Cancer Non Small Cell Lung Cancer Mesothelioma

Start date: 2022-02-14
Primary completion: 2026-06-01
Enrollment: 77

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.